Financing ·
Nuvation Bio Inc. completed a $250.0 million public offering of 0.75% Convertible Senior Notes due 2032, and on July…
NUVB-WTNuvation Bio Inc.
Nuvation Bio Inc. completed a $250.0 million public offering of 0.75% Convertible Senior Notes due 2032, and on July 6, 2026, the underwriters exercised their over-allotment option to issue an additional $37.5 million in Notes. The total aggregate principal amount of Notes sold was $287.5 million, with estimated net proceeds of approximately $277.6 million. Nuvation Bio Inc. is a biotechnology company focused on developing and commercializing oncology-related therapies.